^
Association details:
| Biomarker: | IL2RA-L |
|---|---|
| Cancer: | Follicular Lymphoma |
| Drug: | Opdivo (nivolumab) (PD1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Efficacy and safety results from CheckMate 140, a phase 2 study of nivolumab for relapsed/refractory follicular lymphoma
Published date:
02/04/2021
Excerpt:
A total of 92 patients were treated with nivolumab....In analyses of pre-treatment serum levels of 49 cytokines among 78 patients, soluble interleukin 2 receptor α (sIL-2Rα) levels were lower at baseline in responders per investigator vs non-responders (supplemental Figure 1) as assessed by rank-sum testing (P = .0025)...
DOI:
10.1182/blood.2019004753
Trial ID:
